Bristol-Myers Squibb Appoints José Baselga, M.D., Ph.D. to Board of Directors
6 March 2018 - - New York, New York-based biopharmaceutical company Bristol-Myers Squibb (NYSE: BMY) board of directors has named José Baselga, M.D., Ph.D., to the board, effective March 1, 2018, the company said.
Baselga will serve as a member of science and technology committee of the board of directors.
Baselga is currently the Physician-in-Chief at Memorial Sloan Kettering Cancer Center where he is responsible for the management of patient care and plays an active role in efforts to enhance and expand programs in clinical and translational research. He is also a Professor of Medicine at Weill Cornell Medical College.
He has more than 30 years of clinical and research experience that includes pioneering development of treatments for women with HER2-positive breast cancer and being actively involved in the American Association for Cancer Research, where he has previously served as president.
He served as chief, hematology and oncology division; associate director, Massachusetts General Hospital Cancer Center from 2010 to 2012, and led the Vall d'Hebron Hospital in Barcelona, a comprehensive cancer center from 1996 to 2010. He has served as a Professor of Medicine at both Harvard Medical School and Universitat Autonòma de Barcelona.
Bristol-Myers Squibb's mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.